Abstract:Recently,as the second generation of 20S proteasome inhibitors,peptide boronic acid derivatives have received much more attentions due to their stable metabolism,strong inhibitory activity,high specificity,and low toxicity.However,the structures of proteasome inhibitors are relatively complex and flexible,which cause troubles for structure-based drug design.In this paper,molecular docking was applied to mechanism study on 44 boronic acid derivatives of tyropeptin inhibitors of 20S proteasome.The results showed that main non-covalent interactions between boronic acid derivatives of tyropeptin and proteasome are as follows:(1) H-bond interactions between OH of boronic acid group and ARG19,LYS33,and GLY47;(2) H-bond interactions between atoms of backbone of peptide and THR21,GLY47,and ALA49;(3) Hydrophobic and H-bond interactions between R1 group and S1 pocket of proteasome.Based on the docking conformers,all 44 samples were aligned according to the sketch atoms and then used for following CoMFA and CoMSIA to obtain the optimal CoMSIA model,of which the number of principal component,determination coefficients(r2),standard deviation(S),cross-validated r2(q2),and determination coefficients for external samples(r2pred) of were 3,0.882,0.188,0.494 and 0.756,respectively.Then,de novo molecular design was performed based on two templates with high activities.GA-based structure search algorism and similarity evaluation function was used to guide the evolution process.Five new molecules were obtained according to the rule of Lipinski and as-predicted activities by the optimal CoMSIA model.The inhibitory activities of them are all at nano level.

Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from Β-Amino Acids

Synthesis, in Vitro and in Vivo Biological Evaluation, Docking Studies, and Structure--activity Relationship (SAR) Discussion of Dipeptidyl Boronic Acid Proteasome Inhibitors Composed of Beta-Amino Acids.

Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship (sar) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the Sar of Alpha-Amino Acid Boronates

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Tripeptide Boronic Acid Proteasome Inhibitors

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Structure-Based Drug Design of Diphenyl Α-Aminoalkylphosphonates As Prostate-Specific Antigen Antagonists.

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids

Pharmacophore Modeling, Docking Studies, and Synthesis of Novel Dipeptide Proteasome Inhibitors Containing Boron Atoms

Combined 3D-QSAR, Molecular Docking and Molecular Dynamics Study on Derivatives of Peptide Epoxyketone and Tyropeptin-Boronic Acid As Inhibitors Against the Β5 Subunit of Human 20S Proteasome

Urea-containing Peptide Boronic Acids As Potent Proteasome Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Molecular Docking,3D-QSAR,and Molecular Design of Boronic Acid Derivatives of Tyropeptin Inhibitors of 20S Proteasome

Synthesis and Biological Activity of Peptide Proline-Boronic Acids As Proteasome Inhibitors

Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies

Preparation and Biological Evaluation of Soluble Tetrapeptide Epoxyketone Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Dipeptides As Novel Non-Covalent 20S Proteasome Inhibitors

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors